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Abstract
The rationale and objectives for radioactive iodine (RAI) ablation remain perplexing to many. This review addresses the
meaning, clinical context and the goals of “ablation”: the RAI treatment after a total thyroidectomy. This article also aims
to clarify the definition of a total thyroidectomy and how a thyroid remnant can introduce a confounding factor in the
postoperative management of patients with differentiated thyroid cancer. The implications of an existing thyroid remnant on
RAI diagnostic imaging and serum thyroglobulin levels are discussed. This review provides a rational approach validating the
utility of RAI remnant ablation regardless of the patient’s risk stratification.
Keywords: Radioactive iodine, ablation, thyroid cancer, thyroid remnant, I-131, I-124, dosimetry, beta knife

Öz
Radyoaktif iyot (RAİ) ablasyon kavramı mantığının ve hedeflerinin birçok kişi için hala yeterince açık olmadığını görüyoruz. Bu
makalede total tiroidektomiyi takiben yapılan RAİ “ablasyon” girişiminin anlamı, hedefleri ve klinik değeri izah edilmektedir.
Gerçekçi anlamda total tiroidektominin RAİ ablasyonu ile mümkün olduğu tezini savunuyor ve destekleyen verileri sistematik
olarak sunuyoruz.
Anahtar kelimeler: Radyoaktif iyot, ablasyon, tiroid kanseri, bakiye tiroid dokusu, I-131, I-124, dozimetri, beta knife

Introduction

The rationale for each recommendation is discussed, in
detail, in a scholarly fashion, but yet, there is a sense of
ambiguity in defining the indications for administration
of RAI ablation. This review will discuss the ATA
recommendations from a perspective that accounts
surgical considerations, nuclear medicine principles, and
genomic developments.

The role for radioactive iodine (RAI) in the management
of metastatic differentiated thyroid cancer (DTC) is
indisputable. Its utilization postoperatively as part of
initial treatment, however, is still a matter of debate. The
2015 American Thyroid Association (ATA) guidelines is a
133-page document written in a dissertation format (1).
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The Role of RAI (Including Remnant Ablation,
Adjuvant Therapy, or Therapy for Persistent
Disease) after Thyroidectomy in the Primary
Management of Differentiated Thyroid Cancer

Surgical Anatomy of Total Thyroidectomy,
Sources and Locations of Thyroid Remnants
The strict definition of total thyroidectomy, as it pertains
to subsequent diagnostic and therapeutic considerations,
is the removal of all functioning thyroid tissue. When a
clinical decision is made for a lobectomy, based on a low
risk disease designation, “ablation” is not part of the
equation. Ablation is, in the most simplistic terms, the
eradication of all functional thyroid tissue left behind
after surgical total thyroidectomy. A surgical total
thyroidectomy entails removing the gland in the plane
outside its “true capsule” (Figure 1). The true capsule
is a very fine layer. A faithful dissection over the true
capsule may occasionally pose a significant challenge
to the viable preservation of the parathyroid glands
and safe protection of the recurrent laryngeal nerve
(RLN), as these critical structures have very intimate
anatomic relations with the true capsule (Figure 2). A
rational definition of total thyroidectomy is, therefore,
the removal of the anatomical gland with viable and
non-traumatic preservation of the parathyroid glands
and RLN. It is important to emphasize that injuries to
these critical structures are usually caused by ischemia
resulting from devascularization, or traumatic contusion
due to vigorous dissection and traction, not necessarily
inadvertent transection or resection. A safe dissection,
when performed in a cognizant way, may result (or even
require) entering inside the true capsule and leaving a
focal, thin rim of functional thyroid tissue in situ. A similar
challenge may be encountered dissecting the upper pole
vessels. There is an intimate relationship between the
external branch of the superior laryngeal nerve and the
superior thyroidal artery and vein. The dissection of the
thyroid upper pole can also be challenging, particularly
with a high-riding position. A safe division of the upper
pole vasculature could leave behind a small remnant

2015 ATA Recommendation 51
A) RAI remnant ablation is not routinely recommended
after thyroidectomy for ATA low-risk DTC patients.
Consideration of specific features of the individual
patient that could modulate recurrence risk, disease
follow-up implications, and patient preferences
are relevant to RAI decision-making (Weak
recommendation, low-quality evidence).
B) RAI remnant ablation is not routinely recommended
after lobectomy or total thyroidectomy for patients
with unifocal papillary microcarcinoma, in the absence
of other adverse features (Strong recommendation,
moderate-quality evidence).
C) RAI remnant ablation is not routinely recommended
after thyroidectomy for patients with multifocal
papillary microcarcinoma in the absence of other
adverse features. Consideration of specific features of
the individual patient that could modulate recurrence
risk, disease follow-up implications, and patient
preferences are relevant to RAI decision-making (Weak
recommendation, low-quality evidence).
D) RAI adjuvant therapy should be considered after
total thyroidectomy in ATA intermediate-risk level
DTC patients (Weak recommendation, low-quality
evidence).
E) RAI adjuvant therapy is routinely recommended
after total thyroidectomy for ATA high-risk DTC
patients (Strong recommendation, moderate-quality
evidence).
RAI treatment is given in three distinct settings with
different clinical indications (intents);
1) Ablation of the remnant
2) Adjuvant treatment for residual disease or occult
metastatic disease
3) Therapy for known metastatic disease.
The term “ablation” specifically refers to first-line RAI
treatment after surgical total thyroidectomy.
The specific target of this treatment is normal residual
thyroid tissue, i.e. the remnant, (Table 1). The confusion
regarding the indications of RAI ablation stems from the
underestimation of the impact of the remnant volume and
patterns of uptake on imaging studies following surgical
total thyroidectomy. Certain surgical details need to be
explained in order to clarify the remnant concept from a
clinical context.

Table 1. Radioactive iodine treatment objectives
RAI treatment
intent

Target

Objectives

Ablation

Remnant

Increase specificity of
Tg monitoring
Complete postsurgical staging
Identify/clear
ambiguous foci of
uptake

Adjuvant treatment

Residual disease
Recurrent disease
Metastatic disease

Ablation objectives
Disease control

Therapy

Residual disease
Recurrent disease
Metastatic disease

Disease control

RAI: Radioactive iodine, Tg: Thyroglobulin
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Figure 1. The surgical anatomy and technique of total thyroidectomy, remnant volume. This diagram adapted from Tan et al. (7) shows the fascial
compartments in the thyroid space. The parathyroid glands are situated over the true capsule. The separation of the parathyroid glands off the true capsule
can disrupt the vascular supply. The cranial end of the recurrent laryngeal nerve typically travels under the ligament of Berry and, at this position, is very
close to the true capsule of the thyroid. A vigorous extracapsular dissection may traumatize these vital structures even if they are carefully identified and
avoided during surgery

Figure 2. The image on the left shows a parathyroid gland lying on the thyroid capsule. The image on the right shows the recurrent laryngeal nerve under
the ligament of Berry, and their very intimate relations with the true capsule of the thyroid gland
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metastatic disease. Eradication of these potential sources
of misdiagnosis, while there is still open communication
between the surgeon and the imager, is important. c) The
post-ablation whole-body scan is considered the standard
for extent of disease evaluation.
When postoperative RAI treatment is contemplated with
an adjuvant intent, in addition to the remnant ablation
objectives, RAI is aimed to target residual disease or occult
metastatic disease. When the intent is adjuvant treatment,
risk stratification becomes important in the selection of
the administered activity of I-131. For remnant ablation
purposes only, the risk stratification has no bearing.
Complete thyroidectomy, in the strictest sense, is only
possible with surgical (cold steel knife) thyroidectomy,
followed by I-131 ablation (beta knife). There exists a group
of patients where surgical total thyroidectomy removes
all the functional remnant tissue. Although it could be
argued that RAI ablation is not necessary in this group, it is
challenging to identify these patients using standard clinical
evaluations.

(Figure 3). The pyramidal lobe usually has a short
extension containing functional tissue that becomes a
fibrotic cord as it extends cranially. It is typically divided
at a reasonable length along its tract. Occasionally this
pyramidal cord may also contain functioning thyroid
tissue. The totality of a total thyroidectomy is reliant
on the surgeon’s technique. High volume experienced
surgeons can produce consistent results in terms of low
remnant volume; however, the reality in community
settings could vary widely. The terms near-total or subtotal thyroidectomy are disclosures of not insignificant
remnant volume. Remnant thyroidectomy is accomplished
by RAI ablation.

Radioactive
Iodine
Ablation:
Completion Thyroidectomy

Beta-knife

The therapeutic effect of I-131 works through beta
particles, thus, it has been named a “beta-knife” (2).
The objectives of ablation are three-fold a) Ablation
eradicates all functioning thyroid tissue. With that goal
accomplished, thyroglobulin (Tg) becomes a highly
specific tumor marker. This simply facilitates the postop long-term patient follow-up. b) Ablation wipes out
all focal normal thyroid tissue left in-situ by the surgeon
to avoid injury to laryngeal nerves and parathyroid
glands. From a surgical standpoint, these small clusters
of normal thyroid tissue remnants are inconsequential;
however, they appear as focal areas of RAI uptake on
future imaging studies and can easily be interpreted as

Challenges and Potential Solutions for Accurate
Assessment of Remnant Volume
The volume of the thyroid remnant is highly variable
and is dependent on the surgeon’s technique; it is not
typically highlighted in the operative report and is usually
undetectable by ultrasound (US) or other anatomic imaging
modalities such as computed tomography (CT) or magnetic
resonance imaging (MRI). Serum Tg can provide some
information as to the presence of functioning thyroid
tissue; but the marked variability in Tg levels, which can
overlap with metastatic disease, makes Tg an unreliable
quantitative measure of remnant volume. Occult metastatic
sites may only be detected by a post-ablation scan. Typical
1-5 mCi I-131 imaging has notoriously low sensitivity for
disclosing occult foci.
Postoperative/pre-ablative RAI imaging may be
considered to determine the extent of residual functional
thyroid tissue, or remnant volume. I-131 has become
the mainstay for RAI imaging due to its availability and
relatively low cost; however, one must recognize the
inherent limitations of I-131 as a diagnostic imaging
agent. I-131 has high energy gamma emissions with
the greatest abundance of 364 keV which lead to septal
penetration and limit the spatial resolution of standard
gamma cameras. In addition, only low administered
activities of I-131 can be given for diagnostic purposes
due to concerns for stunning, especially when subsequent
RAI treatment is being considered. Routine diagnostic
I-131 scans are usually performed with administered
activities in the range of 1-5 mCi. These low dose
images are often of limited diagnostic quality and may
underestimate the extent of disease evaluation. Subtle
or non-visualized foci of RAI avid disease on low dose

Figure 3. Normal postoperative radioactive iodine scan. This image shows
a small focus of activity at the midline of the lower neck compatible with a
midline remnant. There are also two small foci of radioactive iodine uptake in
the upper neck, which are equivocal. Upon referring with the surgeon who
performed the operation, these foci were confirmed to represent remnant
activity beneath the superior parathyroid glands. Without knowledge of the
operative findings these can easily be reported as metastatic nodal disease
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diagnostic I-131 scans may become evident on posttreatment scans with therapeutic administered activities
(Figure 4). Even with higher administered activities of
I-131, it can be difficult to differentiate foci of uptake
in the neck as thyroid remnants versus nodal metastatic
disease. RAI avid foci in the neck can be elucidated with
increased confidence only after the thyroid remnant has
been completely ablated. In addition, eliminating the
remnant comprised of highly avid normal thyroid tissue
reduces competition for RAI at metastatic sites thereby
enhancing diagnostic scan sensitivity and therapeutic
efficacy (3).
Although not in routine clinical use currently, I-124 imaging
has been demonstrated to be a very sensitive functional
imaging agent. I-124 positron emission tomography (PET)/
CT has an outstanding spatial resolution in elucidating
small thyroid remnants from the right or left lobes or in
the distribution of the pyramidal lobe (Figure 5). Due to
its anatomic precision, I-124 PET/CT can also distinguish

Mol Imaging Radionucl Ther 2017;26(Suppl 1):16-23

nodal uptake from a remnant in the thyroid bed which may
not be adequately visualized with other imaging modalities.
I-124 has been shown to have a similar performance in
detection of RAI avid lesions as compared to posttherapeutic I-131 scans. Additionally, the risk of stunning at
higher administered activities of I-131 may not be observed
with I-124. Therefore, I-124 may be considered the most
sensitive imaging modality for assessing remnant thyroid
tissue.
Perhaps the greatest merit of I-124 PET/CT is that it allows
accurate quantitation of remnant volume and kinetics for
the purposes of remnant dosimetry. Our group showed
significant variations in cumulated activities and functional
volumes of thyroid remnants between cohort patients.
The maximum remnant activity ranged from 1.2 to 215.9
uCi with the total functional remnant volume (the total
number of voxels within the remnant range of interest)
ranging from 1 to 60 mL. The activity per volume of
remnant tissue ranged from 0.036 to 11.265 uCi/mL. The
total cumulated activity within the remnant ranged from
68 to 12757.3 uCi/hr (4). This variability highlights how
a thyroid remnant may become a confounding factor in
the postoperative management of DTC patients and why
RAI ablation is key to maintaining a standard baseline for
which future imaging and laboratory parameters can be
compared.

Specificity of Thyroglobulin
Tg is a highly specific tumor marker when functioning
thyroid tissue is no longer present, i.e. after total
thyroidectomy and RAI ablation of the remnant. It has
been estimated that 1 g of normal thyroid tissue releases
about 1 ng/mL of Tg into the serum when thyroidstimulating hormone (TSH) is normal and about 0.5 ng/
mL when TSH is suppressed (<0.1 mIU/L) (5). The remnant
volume, and thus remnant-produced Tg, is dependent on
the surgical technique and potentially could be highly
variable/unpredictable.
The factors influencing baseline and recombinant human
TSH stimulated Tg levels in patients with metastatic DTC
were investigated in a study by Robbins et al. (6). The
authors found wide variations in Tg levels and considerable
overlap between metastatic sites. The median baseline Tg
level for cervical metastases was 2 ng/mL and increased
to a median of 8 ng/mL after recombinant human TSH
stimulation. The median baseline and stimulated Tg levels
for mediastinal metastases were 4 ng/mL and 16 ng/mL,
and for distant metastatic sites were 25 ng/mL and 180
ng/mL, respectively. The patients with thyroid remnants
included in the study had a median baseline Tg level of
0.6 ng/mL, with the highest being 66 ng/mL. After
recombinant human TSH, the median stimulated Tg in
patients with thyroid remnants was 1.2 ng/mL but ranged
as high as 250 ng/mL.

Figure 4. Radioactive iodine (RAI) scan with 1 mCi versus 100 mCi
demonstrating occult remnant or nodal disease. The image on the left is
a diagnostic whole body scan with 1 mCi of I-131 showing no abnormal
RAI avid foci in the neck. The image on the right is a posttreatment scan
for the same patient after therapy with 100 mCi of I-131. This image shows
physiologic activity in the salivary glands as well as two RAI avid foci in the
neck that were confirmed to represent nodal metastases
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The Activity of I-131 to be Used for Remnant
Ablation or Adjuvant Therapy

Following Tg levels in patients who have undergone
total thyroidectomy but not RAI ablation is challenging.
The Tg level is expected to increase by at least twofold in the presence of a thyroid remnant under the
influence of recombinant human TSH; however, the
stimulated Tg level has been shown to increase almost
four-fold in some patients. The inconsistent baseline
Tg levels produced by the remnant along with the
documented variability in stimulated Tg levels that
overlap with metastatic disease make it very difficult to
reliably detect occult metastasis. In addition, the natural
progression of an un-ablated thyroid remnant under
TSH suppression and its effect on Tg production are not
clearly established. These issues can be avoided if the
thyroid remnant is ablated with RAI thereby eradicating
all functioning thyroid tissue and rendering Tg a very
specific indicator of recurrent disease in post-surgical
patients.

2015 ATA Recommendation 55
A) If RAI remnant ablation is performed after total
thyroidectomy for ATA low-risk thyroid cancer or
intermediate-risk disease with lower risk features
(i.e., low-volume central neck nodal metastases with
no other known gross residual disease or any other
adverse features), a low administered activity of
approximately of 30 mCi is generally favored over higher
administered activities (Strong recommendation, highquality evidence).
B) Higher administered activities may need to be
considered for patients receiving less than a total or
near-total thyroidectomy in which a larger remnant
is suspected or in which adjuvant therapy is intended
(Weak recommendation, low-quality evidence).

Figure 5. I-124 positron emission tomography/computed tomography image through the level of the thyroid bed shows regions of interest drawn around
a thyroid remnant (blue) and a metastatic right level 3 lymph node (green). The remnant is not measurable by ultrasound or computed tomography. There
is overestimation of functional volume (correctible) due to voxel saturation phenomenon
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2015 ATA Recommendation 56
Administered RAI Activity (mCi) and Radiation
Absorbed Dose (Rad) Relationship
When RAI is intended for initial adjuvant therapy
to treat suspected microscopic residual disease,
administered activities above those used for remnant
ablation up to 150 mCi are generally recommended (in
absence of known distant metastases). It is uncertain
whether routine use of higher administered activities
(>150 mCi) in this setting will reduce structural
disease recurrence for T3 and N1 disease (Weak
recommendation, low-quality evidence).
Currently, the most common practice in RAI ablation
is to use a fixed amount of radioiodine regardless of
the size of the thyroid remnant or the percentage of
radioiodine uptake. Different administered activity levels
have been tested over the years ranging from 30 mCi to
150 mCi. There has been a paradigm shift towards using
less administered activities for RAI remnant ablation
in the setting of low-risk DTC since the publication of
two high-impact articles in the New England Journal of
Medicine in 2012, and further propagated after release
of the 2015 ATA guidelines (8,9). As paradoxical as it
may seem, 30 mCi of radioiodine will completely destroy
the thyroid remnant in some patients whereas 150 mCi
may not be sufficient in others. The explanation is that,
there is no linear relationship between the administered
activity and radiation absorbed dose to the remnant. The
radiation dose (in rads) depends not only on the number
of millicuries administered, but also the percent uptake,
the size of the remnant, and the effective half-life (T1/2
eff) of I-131 in the remnant. Patients with small remnants
and high uptakes may receive a large radiation dose from
30 mCi whereas those with large remnants and low
uptakes may receive a small and inadequate radiation
dose from 150 mCi. In a 1983 dosimetric study, Becker
and Hurley demonstrated a wide variation in uptake and
remnant size in patients who were referred for ablation
(10). There was no correlation between the number of
millicuries administered and the radiation absorbed dose
delivered to the remnant (Figure 6). Although this study
unarguably demonstrated the unreliability of a fixed
or standard amount of radioiodine for ablation, due
to feasibility and logistical considerations a dosimetric
approach never was adapted.
There is a clear need to develop individualized dosimetryguided RAI ablation protocols. I-124 PET/CT offers a
robust quantitative tool to achieve this goal. Active
studies are being performed to determine the technical
prerequisites for a time and cost-conscious standard
protocol.

Figure 6. Lack of correlation between radiation dose to the remnant and
millicuries of radioactive iodine administered. Adapted from (10) Hurley JR,
Becker DV. The use of radioiodine in the management of thyroid cancer.
Freeman LM, Weissman HS (eds). Nuclear Medicine Annual. New York,
Raven Press 1983;329-384.

Summary and Recommendations
Although the potential side effects of RAI are real
and efforts to utilize lower administered activities for
ablation are commendable, this should not overlook the
opportunity for achieving complete ablation. The benefits
of complete remnant ablation in the future follow-up
and management of DTC patients after thyroidectomy
cannot be denied. From a practical standpoint, a total
thyroidectomy usually leaves behind some functioning
thyroid tissue. This postsurgical thyroid remnant cannot
be accurately evaluated/visualized with anatomic imaging
studies like CT or ultrasound, and it can be misleading
on functional RAI imaging indistinguishable from RAI avid
disease in the neck. Moreover, the volume of remaining
thyroid tissue is dependent upon the surgical technique
and invariably and unpredictably affects the Tg level
at baseline and under TSH stimulation. Avoiding RAI
remnant ablation because of the risk of side effects or
the reliance on underpowered, short-term prospective
studies or flawed retrospective analyses fails to recognize
the goals of therapy and the practical approach to the
postoperative follow-up of DTC patients. The therapeutic
administration of RAI to ablate the thyroid remnant allows
for completion of a “true” total thyroidectomy (cold
steel knife + beta knife) and improves the postoperative
management of DTC patients by facilitating RAI imaging
and permitting the use of serum Tg as a highly specific
tumor marker.
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The recommendations below incorporate genomic
profiling for risk stratification and dosimetric approach
for selection of administered activities for RAI ablation.
Proposed Guidelines for RAI Ablation
A) RAI ablation decision should be made at the time
of the surgical treatment decision. Risk stratification
should include genomic profiling. RAI remnant ablation
is routinely recommended after total thyroidectomy,
if the preoperative intent was total elimination
of anatomic and functional thyroid tissue. Main
consideration is the role for Tg monitoring and RAI
imaging surveillance in the long-term management
of patients. RAI ablation should be administered
with radiation absorbed dose to the remnant tissue
optimized.
B) If micropapillary cancer was incidentally
reported in the surgical pathology following a total
thyroidectomy, RAI ablation may be omitted if there is
no histopathologic or genomic risk factor identified.
C) RAI remnant ablation is not indicated after
lobectomy. If a histopathologic or genomic risk factor
is identified, a completion thyroidectomy should be
performed and followed by RAI ablation.
D) If the clinical intent is adjuvant treatment for
suspected/known residual/metastatic disease RAI
ablation should be administered in a therapeutic
context, with radiation absorbed dose to the malignant
disease optimized.
E) Administered activity selection should be
determined based on dosimetric considerations,
for both remnant ablation and adjuvant treatment
indications.
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